BACKGROUND: Imaging plays a pivotal role in the management of multiple myeloma (MM). Besides morphological imaging methods, such as whole-body X‑ray, computed tomography (CT) and magnetic resonance imaging (MRI), the hybrid modality positron emission tomography/CT (PET/CT) using the glucose analogue 18F‑fluorodeoxyglucose (18F‑FDG) as radiotracer is increasingly used. OBJECTIVES: Aim of this review article is to outline the major applications of PET/CT in the diagnosis and management of MM, and to provide hints on the reading and interpretation. MATERIALS AND METHODS: Background knowledge and guideline recommendations on imaging of MM are outlined and complemented by recent study results. RESULTS: Although 18F‑FDG PET/CT is not currently considered a standard method for the diagnosis of MM, it is a very powerful diagnostic tool for the detection of medullary and extramedullary disease, a reliable predictor of survival and the most robust modality for treatment response evaluation. Moreover, it plays a significant role in minimal residual disease (MRD) assessment. On the other hand, practical considerations on local availability and costs limit the widespread use of PET/CT. In addition, false-negative and the seldom false-positive results and the heterogeneity of MM presentation inevitably make interpretation of PET/CT images challenging. CONCLUSIONS: PET/CT has a high value in the diagnosis, prognosis, and assessment of treatment response in patients with MM. Therefore, the role of the modality in the management of the disease is expected to increase in the near future.
BACKGROUND: Imaging plays a pivotal role in the management of multiple myeloma (MM). Besides morphological imaging methods, such as whole-body X‑ray, computed tomography (CT) and magnetic resonance imaging (MRI), the hybrid modality positron emission tomography/CT (PET/CT) using the glucose analogue 18F‑fluorodeoxyglucose (18F‑FDG) as radiotracer is increasingly used. OBJECTIVES: Aim of this review article is to outline the major applications of PET/CT in the diagnosis and management of MM, and to provide hints on the reading and interpretation. MATERIALS AND METHODS: Background knowledge and guideline recommendations on imaging of MM are outlined and complemented by recent study results. RESULTS: Although 18F‑FDG PET/CT is not currently considered a standard method for the diagnosis of MM, it is a very powerful diagnostic tool for the detection of medullary and extramedullary disease, a reliable predictor of survival and the most robust modality for treatment response evaluation. Moreover, it plays a significant role in minimal residual disease (MRD) assessment. On the other hand, practical considerations on local availability and costs limit the widespread use of PET/CT. In addition, false-negative and the seldom false-positive results and the heterogeneity of MM presentation inevitably make interpretation of PET/CT images challenging. CONCLUSIONS: PET/CT has a high value in the diagnosis, prognosis, and assessment of treatment response in patients with MM. Therefore, the role of the modality in the management of the disease is expected to increase in the near future.
Authors: Danielle van Lammeren-Venema; Josien C Regelink; Ingrid I Riphagen; Sonja Zweegman; Otto S Hoekstra; Josée M Zijlstra Journal: Cancer Date: 2011-09-01 Impact factor: 6.860
Authors: Michele Cavo; Evangelos Terpos; Cristina Nanni; Philippe Moreau; Suzanne Lentzsch; Sonja Zweegman; Jens Hillengass; Monika Engelhardt; Saad Z Usmani; David H Vesole; Jesus San-Miguel; Shaji K Kumar; Paul G Richardson; Joseph R Mikhael; Fernando Leal da Costa; Meletios-Athanassios Dimopoulos; Chiara Zingaretti; Niels Abildgaard; Hartmut Goldschmidt; Robert Z Orlowski; Wee Joo Chng; Hermann Einsele; Sagar Lonial; Bart Barlogie; Kenneth C Anderson; S Vincent Rajkumar; Brian G M Durie; Elena Zamagni Journal: Lancet Oncol Date: 2017-04 Impact factor: 41.316
Authors: S Vincent Rajkumar; Meletios A Dimopoulos; Antonio Palumbo; Joan Blade; Giampaolo Merlini; María-Victoria Mateos; Shaji Kumar; Jens Hillengass; Efstathios Kastritis; Paul Richardson; Ola Landgren; Bruno Paiva; Angela Dispenzieri; Brendan Weiss; Xavier LeLeu; Sonja Zweegman; Sagar Lonial; Laura Rosinol; Elena Zamagni; Sundar Jagannath; Orhan Sezer; Sigurdur Y Kristinsson; Jo Caers; Saad Z Usmani; Juan José Lahuerta; Hans Erik Johnsen; Meral Beksac; Michele Cavo; Hartmut Goldschmidt; Evangelos Terpos; Robert A Kyle; Kenneth C Anderson; Brian G M Durie; Jesus F San Miguel Journal: Lancet Oncol Date: 2014-10-26 Impact factor: 41.316
Authors: Twyla B Bartel; Jeff Haessler; Tracy L Y Brown; John D Shaughnessy; Frits van Rhee; Elias Anaissie; Terri Alpe; Edgardo Angtuaco; Ronald Walker; Joshua Epstein; John Crowley; Bart Barlogie Journal: Blood Date: 2009-05-14 Impact factor: 22.113
Authors: Esther G M de Waal; Andor W J M Glaudemans; Carolien P Schröder; Edo Vellenga; Riemer H J A Slart Journal: Eur J Nucl Med Mol Imaging Date: 2016-11-29 Impact factor: 9.236